Literature DB >> 19672895

Overcoming the global crisis: "yes, we can", but also for TB ... ?

Tom H M Ottenhoff1.   

Abstract

Tuberculosis (TB) poses formidable challenges to global health at the public health-, scientific- and political level. Causing almost two million deaths every year, this ancient disease represents a continuing global crisis. The writing on the wall is that TB is resurging in more virulent and treatment-resistant forms. Our tools to combat TB are dangerously out of date and ineffective. Besides new tools (TB drugs, vaccines, diagnostics), we also need new strategies to identify key Mycobacterium tuberculosis/human host interactions, since it is here that we can most likely find Mtb's Achilles' heel. Equally important is that we build high-quality clinical trial capacity and biobanks for TB biomarker identification. But most important is a global commitment at all levels to roll back TB before it outwits us again.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672895     DOI: 10.1002/eji.200939518

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  Suppression of dendritic cell-mediated responses by genes in calcium and cysteine protease pathways during Mycobacterium tuberculosis infection.

Authors:  Jhalak Singhal; Neha Agrawal; Mohit Vashishta; N Gayatri Priya; Brijendra K Tiwari; Yogendra Singh; Rajagopal Raman; Krishnamurthy Natarajan
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

2.  Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection.

Authors:  Emanuela Greco; Gianluca Quintiliani; Marilina B Santucci; Annalucia Serafino; Anna Rita Ciccaglione; Cinzia Marcantonio; Massimiliano Papi; Giuseppe Maulucci; Giovanni Delogu; Angelo Martino; Delia Goletti; Loredana Sarmati; Massimo Andreoni; Alfonso Altieri; Mario Alma; Nadia Caccamo; Diana Di Liberto; Marco De Spirito; Nigel D Savage; Roberto Nisini; Francesco Dieli; Tom H Ottenhoff; Maurizio Fraziano
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-25       Impact factor: 11.205

3.  History of BCG Vaccine.

Authors:  Simona Luca; Traian Mihaescu
Journal:  Maedica (Bucur)       Date:  2013-03

4.  Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen.

Authors:  Anita Ordas; Robert-Jan Raterink; Fraser Cunningham; Hans J Jansen; Malgorzata I Wiweger; Susanne Jong-Raadsen; Sabine Bos; Robert H Bates; David Barros; Annemarie H Meijer; Rob J Vreeken; Lluís Ballell-Pages; Ron P Dirks; Thomas Hankemeier; Herman P Spaink
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

5.  Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals.

Authors:  Susanna Commandeur; Krista E van Meijgaarden; May Young Lin; Kees L M C Franken; Annemieke H Friggen; Jan Wouter Drijfhout; Fredrik Oftung; Gro Ellen Korsvold; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

6.  Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity.

Authors:  Simone A Joosten; Krista E van Meijgaarden; Pascale C van Weeren; Fatima Kazi; Annemieke Geluk; Nigel D L Savage; Jan W Drijfhout; Darren R Flower; Willem A Hanekom; Michèl R Klein; Tom H M Ottenhoff
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

7.  Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa.

Authors:  Gillian F Black; Bonnie A Thiel; Martin O Ota; Shreemanta K Parida; Richard Adegbola; W Henry Boom; Hazel M Dockrell; Kees L M C Franken; Annemiek H Friggen; Philip C Hill; Michel R Klein; Maeve K Lalor; Harriet Mayanja; Gary Schoolnik; Kim Stanley; Karin Weldingh; Stefan H E Kaufmann; Gerhard Walzl; Tom H M Ottenhoff
Journal:  Clin Vaccine Immunol       Date:  2009-06-24

Review 8.  Toward novel vaccines against tuberculosis: current hopes and obstacles.

Authors:  Christoph A Thaiss; Stefan H E Kaufmann
Journal:  Yale J Biol Med       Date:  2010-12

9.  A high-throughput screen for tuberculosis progression.

Authors:  Ralph Carvalho; Jan de Sonneville; Oliver W Stockhammer; Nigel D L Savage; Wouter J Veneman; Tom H M Ottenhoff; Ron P Dirks; Annemarie H Meijer; Herman P Spaink
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

10.  Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.

Authors:  Steven G Smith; Simone A Joosten; Virginie Verscheure; Ansar A Pathan; Helen McShane; Tom H M Ottenhoff; Hazel M Dockrell; Françoise Mascart
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.